Authors : Dr. Wasim Khan; Dr. Navin Agrawal; Dr. Chhavi Agrawal; Dr. Tanuj Chaturvedi; Dr. Sanuj; Dr. Ajinkya Raverkar

Volume/Issue : Volume 11 - 2026, Issue 6 - June

Google Scholar : https://tinyurl.com/235jra8h

Scribd : https://tinyurl.com/5y3fse9j

DOI : https://doi.org/10.38124/ijisrt/26jun1780

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background Allergic rhinitis is a prevalent IgE-mediated inflammatory condition in which the nasal mucosa is characterised by sneezing, nasal obstruction, rhinorrhoea and itching. Intranasal corticosteroids remain the baseline of treatment, whereas hypertonic saline spray is increasingly used as adjunctive therapies. This study compared the efficacy of intranasal steroid nasal spray (fluticasone furoate) with hypertonic saline (normal saline) nasal spray in patients with allergic rhinitis.  Materials and Methods A prospective comparative study was conducted in the Department of Otorhinolaryngology, Index Medical College Hospital and Research Centre, Indore. 60 patients with clinically diagnosed allergic rhinitis were divided into two groups of 30 each. Group A received intranasal steroid nasal spray (fluticasone furoate), while Group B received hypertonic saline (normal saline) nasal spray. Symptom scores, and medication dependency over a two-month follow-up period.  Results Both treatment groups demonstrated significant clinical improvement. However, the intranasal steroid (fluticasone) group showed superior reductions in nasal symptoms and RCAT scores. Mean RCAT scores improved from 17.44 at baseline to 3.84 at two months in Group A compared with 20.52 to 11.92 in Group B. Medication dependency was also significantly reduced among patients receiving fluticasone.  Conclusion Intranasal steroid (Fluticasone furoate) nasal spray was significantly more effective than hypertonic saline (normal saline) nasal spray in controlling symptoms of allergic rhinitis and improving quality of life.

Keywords : Allergic Rhinitis, Intranasal Steroid (Fluticasone Furoate), Hypertonic Saline, RCAT, Intranasal Corticosteroids.

References :

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. Allergy. 2008;63(Suppl 86):8–160.
2. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758–64.
3. Bousquet J, Van Cauwenberge P, Khaltaev N. Quality of life in patients with nasal polyposis or chronic rhinosinusitis compared with patients with allergic rhinitis or asthma. J Allergy Clin Immunol. 2003;111(4):850–5.
4. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007;28(1):3–9.
5. Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Economic impact of allergic rhinitis in Europe. Allergy. 2012;67(11):1355–62.
6. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445–54.
7. Naclerio RM. The late allergic response. Am Rev Respir Dis. 1991;144(3 Pt 2)
8. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2001 revision. J Allergy Clin Immunol. 2001;108(5 Suppl):S147–334.
9. Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008;38(1):19–42.
10. Sheikh A, Hurwitz B. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2005;(1):CD001563.
11. Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008;1(2):145–55.
12. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus topical H1 receptor antagonists for allergic rhinitis: systematic review of RCTs. BMJ. 2012;345:e4163.
13. Wilson AM, Orr LC, Sims EJ. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Allergy. 2004;59(7):687–97.
14. Graf P. Rhinitis medicamentosa: aspects of pathophysiology and treatment. Allergy. 1997;52(34 Suppl):28–34.
15. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55.
16. Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Importance of patient education in allergic rhinitis. Allergy. 2004;59(Suppl 78):17–22. 17. Ratner PH, van Bavel JH, Martin BG, Hampel FC Jr, Howland WC 3rd, Georges G, et al. Intranasal corticosteroids in clinical practice: a systematic review of efficacy and safety. Am J Respir Med.
17. Ramsey D, Scadding G. Saline nasal irrigation for allergic rhinitis.
18. Cochrane Database Syst Rev. 2007;(3):CD006821.
19. Bachert C, Akdis CA, Pfaar O, et al. Biologics for allergic rhinitis: current status and future perspectives. J Allergy Clin Immunol Pract.